Appendicitis
Conditions
Interventions
Remimazolam Tosilate group:Anesthesia induction and maintenance with remimazolam tosilate
Propofol group:Anesthesia Induction and maintenance of propofol
Sponsors
Department of Anesthesiology, the Second Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Patients with complete medical history, including physical examination, vital signs, electrocardiogram and clinical laboratory examination; 2. Patients aged 18-45 years; 3. BMI is 18-30kg / m2, weight is 50-100kg; 4. ASA grades I-II; 5. Patients who voluntarily sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with any abnormal and clinically significant medical examination; 2. Evidence of any clinically relevant concomitant disease; 3. Patients with gastrointestinal, liver, kidney, respiratory system, cardiovascular, metabolic, immune and other diseases; 4. Patients with gastrointestinal surgery history; 5. Patients with myasthenia gravis; 6. Patients with central nervous system diseases (such as epilepsy), mental disorders or other mental nervous system diseases; 7. Patients with a history of postural hypotension, dizziness or vertigo; 8. Patients with chronic or acute infection; 9. Patients with history of allergy / hypersensitivity (including drugs or other substances); 10. Patients who took any medication at least one month before study administration; 11. Patients who participated in the trials of other study drugs within 2 months before or during the trial; 12. Smoker (10 cigarettes or 3 cigars or 3 pipes of cigarettes per day) or unable to prohibit smoking during the test; 13. Subjects of alcohol abuse (more than 60 g / day); 14. Target of drug abuse; 15. Blood donors (more than 100 ml blood donation within 4 weeks before study administration or during the trial); 16. Subjects with excessive physical activity (within 1 week before study administration or during study); 17. Subjects who are unwilling to use contraception or sexual partners are unwilling to use contraception during the trial; 18. People who are known to be allergic to benzodiazepines, flumazenil, anesthetics, or who have contraindications for the use of such drugs; any indication of long-term use of benzodiazepines (such as insomnia, anxiety, spasm) or positive urine drug screening in screening period; 19. Subjects with malampati score of 3 or 4; 20. Any other factors that are not suitable for the subjects to enter the trial in the opinion of the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse reactions during injection; | — |
Secondary
| Measure | Time frame |
|---|---|
| BIS value;Hemodynamic index;Use of vasoactive drugs;Sufentanil dosage;Perioperative adverse events;Unplugging time;Awaking score (MOAA/S);Total amount and time of rimazolom infusion;intraoperative awareness; | — |
Countries
China
Contacts
Public ContactYanwu Jin
The Second Hospital of Shandong University
Outcome results
None listed